Reviva Pharmaceuticals Holdings Inc. Ordinary Shares RVPH 深 沪
已收盘 08-15 16:00:00 美东时间
0.54
+0.074
+15.83%
华盛通- 最 高0.6392
- 今 开0.49
- 成交量 1373.85万股
- 最 低 0.4803
- 昨 收 0.4662
- 总市值 2523.95万
- 52周最高 4.28
- 市盈率 静 --
- 换手率 29.39%
- 52周最低 0.30
- 委 比 0.00%
- 总股本 4673.99万
- 历史最高 15.10
- 量 比 7.84
- 振 幅 34.08%
- 历史最低 0.00
- 每 手 1
- 风险率 0.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Reviva Pharmaceuticals Holdings shares are trading higher after the company reportedbetter-than-expected Q2 EPS results.
Reviva Pharmaceuticals Holdings shares are trading higher after the company rep...
08-15 22:54
【美股盘前】特朗普筹谋鸽派新Fed主席，美股期货涨0.5%，美元指数跌破97，英伟达新高后涨1%，美光科技涨2%
TradingKey - 6月26日周四美股盘前，美国总统特朗普酝酿三到四个下一任美联储鸽派主席，美债利率走低，美元指数跌破97关口，三大美股期货涨约0.50%，英伟达股价创新高后再涨超1%，业绩亮眼的美光科技涨2%。比特币价格守于10.7万，Cicle和Coinbase小幅下跌。
06-26 12:19
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Adial Pharmaceuticals (NASDAQ:ADIL) stock moved upwards by 19.6% to $0...
06-26 05:06
Reviva Pharmaceuticals announces public offering; shares down nearly 15%
Reviva Pharmaceuticals (NASDAQ:RVPH) plans to offer common stock or equivalents and warrants in a public offering. All securities in the offering will be sold by the company. Proceeds will support R&D...
06-26 04:28
Reviva Pharmaceuticals Holdings Announces Proposed Public Offering; No Size Or Amount Disclosed
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system
06-26 04:19
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
Reviva Pharmaceuticals Holdings, Inc. announced plans to offer shares of its common stock and warrants in a public offering, with proceeds to fund research and development, working capital, and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent. The securities are being offered under a shelf registration statement filed with the SEC. Preliminary prospectus supplements and base prospectuses are availa...
06-25 20:17
Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Reviva Pharmaceuticals CEO, Laxminarayan Bhat, Ph.D., will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference on June 16, 2025. The presentation will be available on-demand. Reviva focuses on developing therapies for CNS, inflammatory, and cardiometabolic diseases with two drug candidates, brilaroxazine (RP5063) and RP1208, both with granted composition of matter patents in the U.S., Europe, and other countries. Folde...
06-05 12:00
美股大行评级 | 潜在涨幅417.8%！RBC Capital上调Perspective Therapeutics目标价至16美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136940401951563776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• RBC Capital：维持Perspective Therapeutics(CATX)"跑赢大市"评级，目标价从15美元升至16美元</p> <p>• Canaccord Genuity：维持Taysha Gene Th
06-04 08:35
Reviva Pharmaceuticals Completes Phase 3 Study for Schizophrenia
Reviva Pharmaceuticals Holdings ( ($RVPH) ) has issued an update. On June 2, 20...
06-02 19:29
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Reviva Pharmaceuticals announced positive results from its Phase 3 RECOVER open-label extension (OLE) 1-year study of brilaroxazine for schizophrenia. The study showed robust, sustained broad-spectrum efficacy across all symptom domains, including negative symptoms, with generally good tolerability and low adverse event rates. Brilaroxazine improved neuroinflammatory markers and reduced discontinuation rates. The results support its potential to ...
06-02 11:00
